Complement Split Products and the Pathogenesis of SLE
- 15 December 1988
- journal article
- review article
- Published by Taylor & Francis in Hospital Practice
- Vol. 23 (12) , 45-56
- https://doi.org/10.1080/21548331.1988.11703590
Abstract
Complement's role in SLE pathology is not limited to tissue damage at immune complex deposition sites. Circulating split products can cause inflammatory cells to occlude small vessels and damage their endothelium—all in the absence of IC deposition. In SLE, split-product levels reflect disease activity and predict flares better than conventional complement measurements.Keywords
This publication has 6 references indexed in Scilit:
- Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritisArthritis & Rheumatism, 1988
- Surface expression of gp165/95, the complement receptor CR3, as a marker of disease activity in systemic lupus erythematosusClinical Immunology and Immunopathology, 1988
- Complement activation during systemic lupus erythematosus: C3A and C5a anaphylatoxins circulate during exacerbations of diseaseArthritis & Rheumatism, 1986
- Generation of C5‐derived peptides and other immune reactants in the sera of patients with systemic lupus erythematosusArthritis & Rheumatism, 1984
- Neutrophil Aggregation Induced by Sera from Patients with Active Systemic Lupus ErythematosusArthritis & Rheumatism, 1983
- Reduction by Cimetidine of Serum Parathyroid Hormone Levels in Uremic PatientsNew England Journal of Medicine, 1980